MAPT and Alzheimer disease: Given the significance of amyloid plaque deposition and NFTs formation in the early stages of AD, pharmacological interventions that can lower the Aβ load, prevent tau phosphorylation, or shield sensitive neurons from subsequent pathogenic processes, may stop the resulting cognitive impairments [14].